Wiecek Anna Julia, Jacobson Daniel Hadar, Lason Wojciech, Secrier Maria
Department of Genetics, Evolution and Environment, UCL Genetics Institute, University College London, London, United Kingdom.
UCL Cancer Institute, Paul O'Gorman Building, University College London, London, United Kingdom.
Front Cell Dev Biol. 2021 Jul 9;9:698659. doi: 10.3389/fcell.2021.698659. eCollection 2021.
Tumor mass dormancy is the key intermediate step between immune surveillance and cancer progression, yet due to its transitory nature it has been difficult to capture and characterize. Little is understood of its prevalence across cancer types and of the mutational background that may favor such a state. While this balance is finely tuned internally by the equilibrium between cell proliferation and cell death, the main external factors contributing to tumor mass dormancy are immunological and angiogenic. To understand the genomic and cellular context in which tumor mass dormancy may develop, we comprehensively profiled signals of immune and angiogenic dormancy in 9,631 cancers from the Cancer Genome Atlas and linked them to tumor mutagenesis. We find evidence for immunological and angiogenic dormancy-like signals in 16.5% of bulk sequenced tumors, with a frequency of up to 33% in certain tissues. Mutations in the and oncogenes were positively selected in dormant tumors, suggesting an evolutionary pressure for controlling cell growth/apoptosis signals. By surveying the mutational damage patterns left in the genome by known cancer risk factors, we found that aging-induced mutations were relatively depleted in these tumors, while patterns of smoking and defective base excision repair were linked with increased tumor mass dormancy. Furthermore, we identified a link between APOBEC mutagenesis and dormancy, which comes in conjunction with immune exhaustion and may partly depend on the expression of the angiogenesis regulator as well as interferon and chemokine signals. Tumor mass dormancy also appeared to be impaired in hypoxic conditions in the majority of cancers. The microenvironment of dormant cancers was enriched in cytotoxic and regulatory T cells, as expected, but also in macrophages and showed a reduction in inflammatory Th17 signals. Finally, tumor mass dormancy was linked with improved patient survival outcomes. Our analysis sheds light onto the complex interplay between dormancy, exhaustion, APOBEC activity and hypoxia, and sets directions for future mechanistic explorations.
肿瘤块休眠是免疫监视与癌症进展之间的关键中间步骤,但由于其短暂性,一直难以捕捉和表征。人们对其在不同癌症类型中的普遍性以及可能有利于这种状态的突变背景了解甚少。虽然这种平衡在内部通过细胞增殖与细胞死亡之间的平衡进行精细调节,但导致肿瘤块休眠的主要外部因素是免疫和血管生成方面的。为了了解肿瘤块休眠可能发生的基因组和细胞背景,我们全面分析了来自癌症基因组图谱的9631例癌症中免疫和血管生成休眠的信号,并将它们与肿瘤诱变联系起来。我们在16.5%的批量测序肿瘤中发现了免疫和血管生成休眠样信号的证据,在某些组织中的频率高达33%。在休眠肿瘤中,原癌基因和 癌基因的突变被正向选择,这表明存在控制细胞生长/凋亡信号的进化压力。通过研究已知癌症风险因素在基因组中留下的突变损伤模式,我们发现衰老诱导的突变在这些肿瘤中相对减少,而吸烟模式和碱基切除修复缺陷与肿瘤块休眠增加有关。此外,我们确定了载脂蛋白B编辑酶催化多肽样蛋白(APOBEC)诱变与休眠之间的联系,这与免疫耗竭同时出现,并且可能部分取决于血管生成调节因子 的表达以及干扰素和趋化因子信号。在大多数癌症中,缺氧条件下肿瘤块休眠似乎也受到损害。正如预期的那样,休眠癌症的微环境中富含细胞毒性和调节性T细胞,但也富含巨噬细胞,并且炎症辅助性T细胞17信号减少。最后,肿瘤块休眠与患者更好的生存结果相关。我们的分析揭示了休眠、耗竭、APOBEC活性和缺氧之间的复杂相互作用,并为未来机制探索指明了方向。